Sri Anna, Bailey Kirsten E, Scarborough Ri, Gilkerson James R, Thursky Karin, Browning Glenn F, Hardefeldt Laura Y
Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Parkville, VIC 3010, Australia.
National Centre for Antimicrobial Stewardship, Department of Infectious Diseases Melbourne Medical School and Melbourne Veterinary School, University of Melbourne, VIC 3010, Australia.
One Health. 2024 Aug 26;19:100883. doi: 10.1016/j.onehlt.2024.100883. eCollection 2024 Dec.
In Australia, antimicrobials are given an importance rating by the Australian Strategic and Technical Advisory Group on antimicrobial resistance. High importance antimicrobials are those essential for the treatment or prevention of infections in humans, where there are few or no treatment alternatives. In this study we consulted with experts from across human and animal health using the Delphi consensus-building process to establish the circumstances under which antimicrobials with high importance to human health could be used in animals in Australia. We used three rounds of online surveys. Group responses were provided to participants in each subsequent round to facilitate convergence of opinion. Consensus was defined as 80 % or more of respondents selecting the same option for a question. By the end of the third round, consensus was achieved on eight items. This included the use of high importance antimicrobials being appropriate if culture and sensitivity testing indicated the organism was resistant to low- and medium-rated antimicrobials that could be used to treat the case. If any high-importance antimicrobials are prescribed for animals there was also agreement that a clear indication for this use and justification for antimicrobial choice must be recorded in the medical history, along with the dose rate, route of administration, the duration and the time point for review of the condition and associated antimicrobial therapy. Appropriateness of use of high importance antimicrobials in critically ill animals where culture and sensitivity results are not available is still undefined. Further work is also required to establish which particular organisation should be notified of the use of high importance antimicrobials not registered for use in animals. The Delphi process was valuable in facilitating consensus amongst international experts from a broad range of health backgrounds and experience.
在澳大利亚,抗微生物药物由澳大利亚抗微生物药物耐药性战略与技术咨询小组给出重要性评级。高重要性抗微生物药物是指在治疗或预防人类感染方面必不可少的药物,且几乎没有或没有其他治疗选择。在本研究中,我们采用德尔菲共识达成法,咨询了人类和动物健康领域的专家,以确定对人类健康具有高重要性的抗微生物药物在澳大利亚可用于动物的情况。我们进行了三轮在线调查。在随后的每一轮调查中,都会向参与者提供小组回复,以促进意见趋同。共识定义为80%或更多的受访者对某个问题选择相同的选项。到第三轮结束时,就八项内容达成了共识。这包括,如果培养和药敏试验表明病原体对可用于治疗该病例的低、中评级抗微生物药物耐药,那么使用高重要性抗微生物药物是合适的。如果为动物开具了任何高重要性抗微生物药物,也达成了一致意见,即必须在病历中记录这种使用的明确指征、抗微生物药物选择的理由,以及剂量率、给药途径、疗程以及病情复查和相关抗微生物治疗的时间点。在无法获得培养和药敏结果的重症动物中使用高重要性抗微生物药物的适宜性仍未明确。还需要进一步开展工作,以确定应将未注册用于动物的高重要性抗微生物药物的使用情况通知哪个具体机构。德尔菲法对于促进来自广泛健康背景和经验的国际专家达成共识很有价值。